The Antiparasitic Moxidectin: Safety, Tolerability, and Pharmacokinetics in Humans-Reference-Cited by-同舟云学术

The Antiparasitic Moxidectin: Safety, Tolerability, and Pharmacokinetics in Humans

Published:2003-10 Issue:10 Volume:43 Page:1108-1115
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Cotreau Monette M.,Warren Sarah,Ryan John L.,Fleckenstein Lawrence,Vanapalli Sreenivasa R.,Brown Kenneth R.,Rock David,Chen Chieh-Yu,Schwertschlag Ullrich S.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference39 articles.

1. Population biology of human onchocerciasis;Basanez;Phil Trans R Soc Lond B,1999

2. The reproductive lifespan of Onchocerca volvulus in West Africa savanna;Plaisier;Acta Trop,1991

3. Pathogenesis of onchocercal keratits (river blindness);Hall;Clin Microbiol Rev,1999

4. Immune responsiveness and the pathogenesis of human onchocerciasis;Ottesen;J Inf Dis,1995

5. Onchocerca volvulus and O. lienalis: the microfilaricidal activity of moxidectin compared with that of ivermectin in vitro and in vivo;Tagboto;Ann Trop Med Parasitol,1996

Cited by 126 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Moxidectin versus Ivermectin in the prevention and treatment of acute and chronic experimental trichinellosis;Experimental Parasitology;2024-07

2. [Translated article] Spanish Academy of Dermatology and Venereology (AEDV) expert recommendations for the management of sexual transmitted parasitosis. Scabies, and pediculosis pubis;Actas Dermo-Sifiliográficas;2024-05

3. Onchocerca volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 mg moxidectin or 150 µg/kg ivermectin: results of a randomized double-blind Phase 3 trial in the Democratic Republic of the Congo, Ghana and Liberia;Parasites & Vectors;2024-03-15

4. Efficacy and safety of moxidectin compared with ivermectin against Strongyloides stercoralis infection in adults in Laos and Cambodia: a randomised, double-blind, non-inferiority, phase 2b/3 trial;The Lancet Infectious Diseases;2024-02

5. Onchocerciasis Part I;Neglected Tropical Diseases;2024